title: Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension.
abstract: BACKGROUND
  Pancreatic exocrine insufficiency (PEI) often occurs following pancreatic surgery.
  
  
  OBJECTIVE
  To demonstrate the superior efficacy of pancreatin 25 000 minimicrospheres (Creon 25000 MMS; 9-15 capsules/day) over placebo in treating PEI after pancreatic resection.
  
  
  METHODS
  A 1-week, double-blind, randomised, placebo-controlled, parallel-group, multicentre study with a 1-year, open-label extension (OLE). Subjects ≥18 years old with PEI after pancreatic resection, defined as baseline coefficient of fat absorption (CFA) <80%, were randomised to oral pancreatin or placebo (9-15 capsules/day: 3 with main meals, 2 with snacks). In the OLE, all subjects received pancreatin. The primary efficacy measure was least squares mean CFA change from baseline to end of double-blind treatment (ancova).
  
  
  RESULTS
  All 58 subjects randomised (32 pancreatin, 26 placebo) completed double-blind treatment and entered the OLE; 51 completed the OLE. The least squares mean CFA change in the double-blind phase was significantly greater with pancreatin vs. placebo: 21.4% (95% CI: 13.7, 29.2) vs. -4.2% (-12.8, 4.5); difference 25.6% (13.9, 37.3), P < 0.001. The mean ± s.d. CFA increased from 53.6 ± 20.6% at baseline to 78.4 ± 20.7% at OLE end (P < 0.001). Treatment-emergent adverse events occurred in 37.5% subjects on pancreatin and 26.9% on placebo during double-blind treatment, with flatulence being the most common (pancreatin 12.5%, placebo 7.7%). Only two subjects discontinued due to treatment-emergent adverse events, both during the OLE.
  
  
  CONCLUSIONS
  This study demonstrates superior efficacy of pancreatin 25 000 over placebo in patients with PEI after pancreatic surgery, measured by change in CFA. Pancreatin was generally well tolerated at the high dose administered (EudraCT registration number: 2005-004854-29).
authors: Department of General, Visceral and Vascular Surgery, Josephs-Hospital Warendorf, Warendorf, Germany. c.seiler@jhwaf.de
authors: C M
authors: CM
authors: Seiler
authors: J
authors: J
authors: Izbicki
authors: L
authors: L
authors: Varga-Szabó
authors: L
authors: L
authors: Czakó
authors: J
authors: J
authors: Fiók
authors: C
authors: C
authors: Sperti
authors: M M
authors: MM
authors: Lerch
authors: R
authors: R
authors: Pezzilli
authors: G
authors: G
authors: Vasileva
authors: A
authors: A
authors: Pap
authors: M
authors: M
authors: Varga
authors: H
authors: H
authors: Friess
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004311:Double-Blind Method; D004337:Drug Carriers; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D010179:Pancreas / Q000601:surgery*; D010194:Pancreatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010316:Particle Size; D011183:Postoperative Complications; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004337:Drug Carriers; D005765:Gastrointestinal Agents; D010194:Pancreatin
references: J Gastrointest Surg. 2007 Aug;11(8):949-59; discussion 959-60
references: 17534689
references: Clin Ther. 2010 Jan;32(1):89-103
references: 20171415
references: Clin Exp Gastroenterol. 2011;4:55-73
references: 21753892
references: N Engl J Med. 2007 Feb 15;356(7):676-84
references: 17301298
references: Digestion. 1999;60 Suppl 1:104-10
references: 10026442
references: Med Care. 1992 Jun;30(6):473-83
references: 1593914
references: Med J Aust. 2010 Oct 18;193(8):461-7
references: 20955123
references: Cancer. 1983 Jul 15;52(2):346-52
references: 6305473
references: Gut. 2005 Jun;54 Suppl 5:v1-16
references: 15888770
references: Pancreatology. 2013 Mar-Apr;13(2):133-9
references: 23561971
references: J Biol Chem. 1949 Jan;177(1):347-55
references: 18107439
references: HPB (Oxford). 2009 Dec;11 Suppl 3:3-6
references: 20495625
references: Lancet. 2011 Apr 2;377(9772):1184-97
references: 21397320
references: Curr Gastroenterol Rep. 2007 Apr;9(2):116-22
references: 17418056
references: Ann Oncol. 2010 May;21 Suppl 5:v55-8
references: 20555103
references: S Afr Med J. 2010 Dec 01;100(12 Pt 2):845-60
references: 21414280
references: Med Care. 1993 Mar;31(3):247-63
references: 8450681
references: J Cyst Fibros. 2009 Dec;8(6):370-7
references: 19815466
references: Aliment Pharmacol Ther. 2011 May;33(10):1152-61
references: 21418260
references: Pain Pract. 2011 Sep-Oct;11(5):492-505
references: 21676159
references: J Gastrointest Surg. 2012 Aug;16(8):1487-92
references: 22711213
references: Aliment Pharmacol Ther. 2012 Sep;36(5):426-36
references: 22762290
references: Curr Treat Options Gastroenterol. 2007 Oct;10(5):355-68
references: 17897574
references: Am J Gastroenterol. 2000 Aug;95(8):1932-8
references: 10950038
references: Am J Gastroenterol. 2010 Oct;105(10):2276-86
references: 20502447
references: Best Pract Res Clin Gastroenterol. 2010 Jun;24(3):337-47
references: 20510833
references: Pancreas. 2006 Aug;33(2):156-62
references: 16868481